Evidence map›Paper›PMID 38024241›Full record

ArticleNeuro-oncology advances

Longitudinal characteristics of T2-FLAIR mismatch in IDH-mutant astrocytomas: Relation to grade, histopathology, and overall survival in the GLASS-NL cohort.

Karin A van Garderen, Wies R Vallentgoed, Anna Lavrova, Johanna M Niers, Wendy W J de Leng, Youri Hoogstrate, Iris de Heer, Bauke Ylstra, Erik van Dijk, Stefan Klein and 10 more

Open access · goldAbstract read
In one paragraph

Article in Neuro-oncology advances. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.4field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. An Expanded T2-FLAIR Mismatch Phenotype in IDH-Mutant Astrocytomas.Journal of magnetic resonance imaging : JMRI · 2026
    Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 6 institutions in 2 countries.

Karin A van GarderenDepartment of Radiology & Nuclear Medicine, Erasmus MC, Rotterdam, The Netherlands.ORCID https://orcid.org/0000-0001-9610-4397
Wies R VallentgoedBrain Tumor Center, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.ORCID https://orcid.org/0000-0001-6373-7710
Anna LavrovaDepartment of Radiology & Nuclear Medicine, Erasmus MC, Rotterdam, The Netherlands.ORCID https://orcid.org/0000-0001-9327-8420
Johanna M NiersDepartment of Neurology, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.ORCID https://orcid.org/0000-0002-0366-8247
Wendy W J de LengDepartment of Pathology, UMC Utrecht, Utrecht, The Netherlands.ORCID https://orcid.org/0000-0003-2911-6018
Youri HoogstrateBrain Tumor Center, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.ORCID https://orcid.org/0000-0003-2166-0676
Iris de HeerBrain Tumor Center, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.ORCID https://orcid.org/0000-0003-3178-7603
Bauke YlstraCancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.ORCID https://orcid.org/0000-0001-9479-3010
Erik van DijkCancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.ORCID https://orcid.org/0000-0002-6272-2039
Stefan KleinDepartment of Radiology & Nuclear Medicine, Erasmus MC, Rotterdam, The Netherlands.ORCID https://orcid.org/0000-0003-4449-6784
Kaspar DraaismaDepartment of Neurosurgery, UMC Utrecht, The Netherlands.ORCID https://orcid.org/0000-0002-6003-9607
Pierre A J T RobeDepartment of Neurosurgery, UMC Utrecht, The Netherlands.ORCID https://orcid.org/0000-0001-7845-6196
Roel G W VerhaakJackson Laboratory for Genomic Medicine, Farmington, CT, USA.ORCID https://orcid.org/0000-0003-2773-0436
Bart A WestermanDepartment of Neurosurgery, Amsterdam UMC, Amsterdam, The Netherlands.ORCID https://orcid.org/0000-0002-9898-9616
Pim J FrenchBrain Tumor Center, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.ORCID https://orcid.org/0000-0002-0668-9529
Martin J van den BentBrain Tumor Center, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.ORCID https://orcid.org/0000-0001-5710-5127
Mathilde C M KouwenhovenDepartment of Neurology, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.ORCID https://orcid.org/0000-0001-5252-4365
Johan M KrosDepartment of Pathology, Erasmus MC, Rotterdam, The Netherlands.ORCID https://orcid.org/0000-0002-4727-0724
Pieter WesselingDepartment of Pathology, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.ORCID https://orcid.org/0000-0001-5453-5201
Marion SmitsDepartment of Radiology & Nuclear Medicine, Erasmus MC, Rotterdam, The Netherlands.ORCID https://orcid.org/0000-0001-5563-2871
Erasmus MC · NLAmsterdam University Medical Centers · NLUtrecht University · NLJackson Laboratory · USPrincess Máxima Center · NLUniversity Medical Center Utrecht · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The T2-FLAIR mismatch sign is defined by signal loss of the T2-weighted hyperintense area with Fluid-Attenuated Inversion Recovery (FLAIR) on magnetic resonance imaging, causing a hypointense region on FLAIR. It is a highly specific diagnostic marker for IDH-mutant astrocytoma and is postulated to be caused by intercellular microcystic change in the tumor tissue. However, not all IDH-mutant astrocytomas show this mismatch sign and some show the phenomenon in only part of the lesion. The aim of the study is to determine whether the T2-FLAIR mismatch phenomenon has any prognostic value beyond initial noninvasive molecular diagnosis. Methods: Patients initially diagnosed with histologically lower-grade (2 or 3) IDH-mutant astrocytoma and with at least 2 surgical resections were included in the GLASS-NL cohort. T2-FLAIR mismatch was determined, and the growth pattern of the recurrent tumor immediately before the second resection was annotated as invasive or expansive. The relation between the T2-FLAIR mismatch sign and tumor grade, microcystic change, overall survival (OS), and other clinical parameters was investigated both at first and second resection. Results: The T2-FLAIR mismatch sign was significantly related to Grade 2 (80% vs 51%), longer post-resection median OS (8.3 vs 5.2 years), expansive growth, and lower age at second resection. At first resection, no relation was found between the mismatch sign and OS. Microcystic change was associated with areas of T2-FLAIR mismatch. Conclusions: T2-FLAIR mismatch in IDH-mutant astrocytomas is correlated with microcystic change in the tumor tissue, favorable prognosis, and Grade 2 tumors at the time of second resection.

Indexed as

astrocytomagliomamagnetic resonance imaging

Identifiers

PMID38024241
PMCPMC10681663
OpenAlexW4388601833

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.